The regulation of the 55kDa TNF receptor (TNF-R) mRNA synthesis, membrane expression, and TNF binding factor (BF) release was examined in resting and activated human monocytic THP-I and human promyelocytic leukemia HL-60 cells in vitro. Cells were activated with phorbol myristate acetate (PMA) and bacterial lipopolysaccharide (LPS). TNFa cytolytic activity in the supernatant of THP-1 cells stimulated by PMA began to appear at 4 hr, reached a peak at 8 hr. and declined by 12 hr. For THP-1 cells stimulated with LPS, the peak of TNFa activity appeared at 4 hr and then declined. TNFa-binding sites on the cell membrane were down-regulated within I hr after PMA and LPS treatment and then reappeared 12 hr later. Fifty-five-kilodalton TNF-R mRNA expression during this time period did not correlate with the level of membrane TNFbinding site expression.
Additional studies indicated the presence of a 30-kDa TNF-BF in the supernatants which appeared after 24 hr. These data suggest that activated THP-I and HL-60 cells are capable of releasing TNF-BF into the supernatant and this material may be involved in the control of secreted TNFLu activities.
INTRODUCTION
Native tumor necrosis factor (TNFa) is a 55,000-MW trimer comprised of 17,350 MW peptides (1). TNFa is produced by activated macrophages, lymphocytes, and other cell types in special situations (2) . This cytokine has a spectrum of effects on cells in vitro and tissues in vivo and has important roles in various phases of cellmediated immune reaction (3) .
The mechanism through which TNFa mediates its bioactivity is initiated by first binding to specific ceil membrane receptors (TNF-R) (4) . Subsequent to human TNFa binding to its membrane receptor on cells in vitro, the complex disappears from the membrane and the receptor can be internalized, degraded, or recycled (5-7). Binding is specific; however, the response which this cytokine elicits is dependent on the type of target cell or tissue to which it has attached. Cells from many different tissue sources express low numbers of TNF-R (3-lO,OOO/celI) with dissociation constants (&) ranging from 1.3 X 1 Oe9 M to 7.0 X lo-" A4 (8, 9) . Most cells express a single class of receptor; however, myeloid cells express both high-and low-affinity receptors (10) . A recent report suggests that the high-and low-affinity receptors are distinct and differ in size, glycosylation, and their peptide maps (11) . TNFa! and lymphotoxin (LT or TNF@ have been shown to bind to the same receptors on the human histiocytic cell lines U-937 (11) . Estimates of the size of the TNF-R, as determined by affinity-labeling studies from several groups, range from 55 to 310 kDa (12, 13) . Recently, several groups, including ours, have cloned two distinct human TNFa! receptors which were 55 kDa and 68-75 kDa (14) (15) (16) .
In vitro studies reveal different agents and treatments can rapidly up-and downregulate the expression of TNF-R on both lymphoid and nonlymphoid cells. Stimulation with bacterial lipopolysaccharide (LPS) (6), phorbol myristate acetate (PMA), IL-1 and TNFa itself rapidly downregulates TNF-R expression on human monocytes, macrophages, and promyelocytic leukemia cell line HL-60 (17) . Most investigators have thought that downregulation in these cultures was due to internalization and degradation of TNFa receptor; however, release is an important alternative which was not considered.
Several groups have identified two soluble TNF-R in human urine and we have identified one of these receptors, in the serum of human cancer patients, that is capable of specifically binding to and inactivating human TNF cytolytic activity in vitro (18) (19) (20) (21) (22) . These soluble TNF receptors have molecular weights of 28 to 30 kDa and appear to be derived from the N-terminal extracellular region of the 55-and 75-kDa TNF cell membrane receptors (23) . Other groups have identified cell surface receptors in biological fluids that are released and specifically bind to other biological response modifiers such as IL-2, IL-4, and growth factors (24) (25) (26) . Collectively, these studies have led to the concept that release of soluble receptors may represent a new mechanism to specifically control cytokine activity. This concept is supported by the recent report of Gatanaga et al. (23) that human soluble TNF-R can block the anti-tumor activity of recombinant human TNFa when injected into Meth-A tumor-bearing BALB/c mice. It is not yet clear what the cell and tissue source of these BF may be; however, a recent report by Porteu and Nathan (27) indicates that activated human neutrophils can release TNF-R derived from both 55 and 68-75 kDa receptors. The present study was initiated to examine some of the stages in the synthesis of TNF-R message, membrane expression, and release of TNF-BF in the LPS-and PMA-stimulated macrophagelike cell lines THP-1 and HL-60. 
MATERIALS AND METHODS

Reagents
RNA Isolation and Northern Blotting Analysis
Total cellular RNA was isolated from THP-I and HL-60 cells by the guanidinium isothiocyanate/cesium chloride method and quantitated spectrophotometrically as previously described (3 1). Ten micrograms RNA was electrophoresed in 2.2 M formaldehyde in 1.2% agarose gels, transferred to nitrocellulose filter (Schleicher & Schuell, Keene, NH), and baked at 80°C for 2 hr as described (32) . Filters were hybridized with 32P-labeled TNFa and TNFol receptor-specific synthetic probes. After hybridization, filters were washed at 25°C with 2X SSC, 0.1% SDS for 30 min then at 25 or 42°C with 0.1 X SSC, 0.1% SDS for 30 min. Filters were then exposed to X-Omat XAR-5 (Kodak, Rochester, NY) X-ray films at -70°C. The amount of the RNA was confirmed by ethidium bromide (0.5 mg/ml) staining.
Iodination qfrTNFor and Binding Assay
Two hundred micrograms of rTNFa were equilibrated in PBS(-) by exhaustive dialysis against PBS(-) in 6-8000 MW cutoff Spectra-por dialysis tubing (Spectrum Medical, Inc, Los Angeles, CA). After the dialysis, rTNFLv was concentrated using Speed Vat Concentrator (Savant, NY). The final concentration of rTNFcv was 2 mg/ ml. The rTNFLv iodination procedure was performed as described by Bolton et al. (33) . The rTNFcY (100 pg) in 20 ~1 of 0.1 M sodium borate buffer, pH 8.5, was added to the dried iodinated ester and the reaction mixture (Bolton-Hunter Reagent, Monoiodo '25I DuPont, Wilmington, DE). Free iodine was removed by gel filtration over 3 > a NAP-5 column (Pharmacia, Sweden) with PBS(-) containing 5 mg gelatin. Fractions of 150 ~1 were collected and l-p1 aliquots were assayed by Clinigamma counter (Pharmacia, LKB, Uppsala, Sweden). Peak fractions were pooled, and the specific activity was determined to be 5400 cpm/ng. The labeled material was stored at 4°C and used within 1 month. One million cells were incubated with binding buffer (RPM1 1640 + 10% FBS) in 24-well plates and then incubated with 0.5 ng-30 ng of 1251-labeled TNFa in the presence or absence of a loo-fold excess of unlabeled rTNFa. After a 3-to 4-hr incubation at 4°C binding buffer was removed and the cells were washed 2-4 times with ice-cold PBS(-) (34) . Cells were solubilized in 1 ml of 0.3 N NaOH and radioactivity was determined by gamma counter. When the effect of PMA and LPS on rTNFa binding was examined, unless indicated otherwise, cells were incubated with LPS and PMA at 37°C before the binding assay.
Biosynthetic Labeling of TNF-R.
There are cysteine-rich domains in the TNFa receptor (12) . Therefore, we decided to use [35S]cysteine to label cells. THP-1 cells (3 X lo7 cells) were washed by PBS(-), suspended in 10 ml of cysteine-free RPM1 1640 (Select-Amine Kit, GIBCO) containing 10% dialyzed FBS and [35S]cysteine 50 &i/ml (sp act 1113.6 Ci/mmol) (DuPont, Wilmington, DE), and then incubated with PMA and LPS for 24 hr. After the 24-hr incubation, supernatants were collected and used in cross-linking assays.
Cross-linking Assay
One-milliliter culture supernatants were co-incubated with 1 ng of '251-labeled TNFa for 2 hr at 37°C. Similarly, l-ml culture supernatants from 35S-labeled cells were coincubated with 1 ng of cold TNFa for 2 hr at 37°C. BS3nonreversible linker (34) and DTSSP-thiol reversible linker (35) (Pierce, Rockford, IL) were then added to a final concentration of 5 mM, respectively. After 20 min on ice, the reaction was stopped by adding 20 mM glycine (36) . Five microliters of rabbit anti-hTNFa polyclonal anti-serum was then added and the mixture was incubated for 2 hr at room temperature. Finally, 10 ~1 of immunoprecipitin (BRL, Gaithersburg, MD) (37) was added and the mixture was incubated overnight at 4°C. The samples were centrifuged and the precipitates were washed in 50 mM Tris, pH 7.5, once containing 0.005% Tween-20 and were resuspended in SDS-PAGE buffer with 100 mA4 2-mercaptoethanol (J. T. Baker, NJ).
SDS-PAGE
SDS-PAGE was performed under reducing conditions according to the technique of Laemmli (38) . The gels were dried and exposed to X-Omat XAR-5 films (Kodak). The intensities of bands were determined by scanning with a fiber optic scanner Model 800 (Kontes, Vineyard, NJ). PMA. Stimulation with 5 pg/ml LPS resulted in TNFa production which peaked at 4 hr and then declined thereafter (Fig. 1 B) . HL-60 cells produced TNFcr after treatment with an optimal dose of PMA ( Fig. 1 A, inset) , but did not produce TNFa when stimulated with the levels of LPS we employed in these studies (data not shown). All the cytolytic activity could be neutralized by polyclonal rabbit anti-human TNFa antibody (data not shown).
RESULTS
Induction of
The Effect of PMA and LPS Stimulation on the Expression of TNFa Cell Membrane Receptors
The binding of '251-labeled TNFa to unstimulated and PMA-and LPS-stimulated THP-1 cells was examined as described under Materials and Methods. Specific binding of '251-labeled TNFol was saturable, reaching the maximum at 30 ng of '251-labeled TNFcr ( Fig. 2A) . Scatchard analysis of these data ( Fig. 2A, inset) indicated that there was a single class of binding sites. There were approximate 1848/tell in THP-1 cells. Preexposure of IO-* M PMA for 1 hr rapidly down-regulated the number of 1251-labeled TNFa binding sites by 95-99% (Fig. 2B) . After 12 hr, the number of TNFar membrane receptors was still only 13% of normal. LPS (5 pg/ml) induced downregulation of '251-labeled TNFa binding sites at 1 hr by 70%, then the number of TNFabinding sites increased back up to the level of untreated controls by 12 hr (Fig. 2B ). The affinities ranged from 1.2 X lo-" M to 7.7 X IO-" M (0 hr, 5.0 X -lo M; TPA 1 hr, 7.2 X lo-" M; 4 hr, 7.7 X lo-" M; 12 hr, 1.2 X lo-" AI; LPS 1 hr, 6.8 X lo-" AI; 4 hr, 4.2 X lo-" M; 12 hr, 1.2 X 10-l' J4). Similar results were observed with HL-60 cells as previously reported by Ding et al. (6) .
Examination
of the Level of 55 kDa TNF-R mRNA in THP-1 Cells after PMA and LPS Treatment
As described under Materials and Methods, we next examined whether the levels of mRNA transcript for 55-kDa TNF-R is affected when stimulated with PMA or LPS. We treated THP-1 cells with PMA or LPS for 30 min to 12 hr, then the total RNA was extracted and analyzed for the presence of TNFa and 55-kDa TNF-R mRNA by Northern blotting. As shown in Fig. 3A , the level of 55-kDa TNF-R mRNA of THP-1 cells stimulated with LPS remained relatively constant. When stimulated with PMA, the level of 55-kDa TNF-R mRNA of THP-1 cells showed some fluctuation during the first 12-hr period (Fig. 3B) . The pattern of the mRNA expression did not correlate with the change of the TNFa-binding sites expression on cell membrane. The 55-kDa TNF-R mRNA level in HL-60 cells was unaffected by exposure to LPS during the same time period (Fig. 3E) . The level of TNFa mRNA of THP-1 cells showed a slight increase after LPS and PMA activation (Figs. 3C and 3D ). Release of TNF-Binding Factor (BF) by LPS and PA4A Activated THP-1 Cells in Vitro
We next examined the 24-hr supernatants from resting and stimulated cells for the presence of TNF-BF. In the first study, the 24-hr supematant was incubated with '251-labeled TNFQ in the presence of reversible or nonreversible cross-linkers. The complex was immunoprecipitated by polyclonal rabbit anti-human TNFa antibody and then analyzed on reducing SDS-PAGE (Fig. 4A) . A 55-kDa band of cross-linked rTNFa trimer was visible in each lane, and an extra band of 85 kDa was detected in lanes treated with PMA, LPS, and the 24-hr THP-1 cell control (Fig. 4A, a-c) . The intensity of the 85-kDa bands which were treated with PMA and LPS showed a 129% (b) and 81% (c) increase compared to the control (a) (Fig. 4A, b, c) . This 85-kDa extra band disappeared in lanes using reversible linkers. The 85-kDa band appeared to be due to the combination of the 55-kDa rTNFa trimer and a 30-kDa TNFcr-binding factor. The soluble TNFa receptor we reported (23) and TNF-BF in general has a molecular weight (28 kDa) very close to this range (19) (20) (21) . In a second set of experiments, we cultured THP-1 cells with 35S-labeled cysteine. The supernatants were processed the same as the above except that the rTNFa was not radio-labeled (Fig. 4B) . The same 85-kDa bands were observed in activated lanes (Fig. 4B, f, g ).
The band intensities increased 90%(f) in the PMA-treated sample and 120%(g) in the LPS-treated sample. These result confirmed the presence of a 30-kDa TNFol binding factor induced by PMA and LPS. These same data had been observed three times in different experiments. Similar results were obtained from HL-60 (data not shown).
DISCUSSION
Recently, a soluble form of the extracellular domain of the 55-kDa TNF membrane receptor has been isolated and identified in cancer patient serum (23) (23) . These data suggested that these soluble TNF-R may have an important role in controlling the action of TNFa and LT activities. However, the cellular origin and the mechanism(s) which regulate the source of this soluble receptor remained unclear.
Both LPS and PMA can induce TNF secretion by the human monocytic cell lines THP-1 and the promyelocytic leukemia cell line HL-60 in vitro (38) (39) (40) . We also found TNFa! secretion after the cells were stimulated with optimal levels of PMA and LPS. Northern blotting showed the mRNA for the 55-kDa receptor increased during a l-to 12-hr period. But, the cytolytic activity of supernatant TNFa began to decline near the end of this time period. One possible explanation for the loss of secreted TNF activity is the appearance of an inhibitory factor in the supematants. While we could not distinguish between 55 and 68-kDa TNF membrane receptors, we found that the level of 55-kDa TNF-R mRNA transcripts did not correlate with the significant drop in the expression of membrane TNFa-binding sites after PMA and LPS stimulation. Studies were conducted to determine if TNF-BFs were released into the supematants by resting cells and cells stimulated with PMA and LPS. These studies revealed that these supematants contained a 30-kDa material which specifically bound to radiolabeled TNFa. We also demonstrated [35S]cysteine-labeled 30-kDa material binding to unlabeled TNFa. The molecular weight of this material is close to the MW of soluble TNFa receptors found in urine (18, 19) and in cancer patient's serum (23) . This BF may be responsible for the drop in supematant TNFa activities observed in these cultures. The present study indicated that HL-60 and THP-1 cell lines, which resemble human macrophages, may release TNF-BF as well as TNF. Previous investigators have shown TNFa and TNF-R complexes are rapidly internalized when formed on the cell surface (7). The downregulation observed for TNFa receptors in our studies might be due to internalization. However, downregulation of TNFa membrane receptors may also be due to the release of TNFa receptor(s). The mechanism of how these receptors are released is not yet apparent; however, there are several possibilities: (A) "shedding" directly from the membrane due to enzymatic cleavage, or (B) "secreted" after they have been endocytosed and cleaved by certain enzymes.
Shedding or release of membrane receptors for cytokines may represent a new mechanism of control of these highly active proteins. Release of IL-2 and IL-6 receptors has been reported by Rubin et al. (24) and Novick et al. (23, respectively. Weisman et al. (42) recently reported a soluble human complement membrane receptor type 1 which is biologically functional in viva. These authors have suggested that this may represent a mechanism(s) to control secreted cytokines. The present study shows that TNFa-secreting human cell lines can release soluble TNF-BF when TNFti secretion was stimulated. Whether this release was caused by PMA and LPS, TNFa itself, or some other mechanism(s) is not yet clear. Further studies must be done in this system to: (A) specifically identify whether these BF are derived from 55 or 68-kDa receptors and (B) investigate the molecular mechanism leading to the release of the soluble TNF-R and TNF-BF. Studies of the mechanism(s) resulting in TNF-R release may help us understand the physiological and pathological roles of soluble TNF-R in immunological and cell-mediated reactions.
